EVIDENCE TAKEAWAY
The short answer.
PT-141 is commonly marketed more broadly than the evidence allows. The decision-grade record concerns FDA-reviewed bremelanotide, its subcutaneous formulation, and one narrow population and indication.
WHAT IS PT-141 / BREMELANOTIDE?
Start with identity.
A melanocortin receptor agonist; bremelanotide is FDA approved for one narrowly defined indication under the Vyleesi label.
- Entity type
- Melanocortin receptor agonist
- Research category
- Sexual Health
- Names and aliases
- PT-141 / Bremelanotide · Bremelanotide · Vyleesi
HUMAN VS PRECLINICAL
What evidence exists for PT-141 / Bremelanotide?
Two randomized phase 3 trials support branded bremelanotide for acquired, generalized HSDD in premenopausal women.
Mechanism and nonclinical safety were evaluated as part of product development; the clinical conclusion remains indication-specific.
RESEARCH INTENT
What is PT-141 / Bremelanotide being studied for?
Current source-backed research areas include the topics below. Inclusion means the area is being investigated; it does not establish a treatment benefit.
- 01Hypoactive sexual desire disorder
- 02Melanocortin receptors
- 03Sexual distress
- 04Female sexual health
U.S. REGULATORY STATUS
Is PT-141 / Bremelanotide FDA approved?
Bremelanotide is FDA approved as Vyleesi only for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not indicated for men, postmenopausal women, or sexual performance enhancement.
SPORT STATUS
Is PT-141 / Bremelanotide prohibited in sport?
Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.
Anti-doping rules and product ingredients can change. Athletes should verify the current official list and the exact product before making a real decision.
EVIDENCE LIMITS
What can the current record not establish?
COMMON SEARCH INTENTS
Reviewed questions about PT-141 / Bremelanotide.
What is the evidence for PT-141 / Bremelanotide?
PT-141 is commonly marketed more broadly than the evidence allows. The decision-grade record concerns FDA-reviewed bremelanotide, its subcutaneous formulation, and one narrow population and indication.
3 sources ResearchWhat is PT-141 / Bremelanotide being studied for?
Current source-backed research areas include Hypoactive sexual desire disorder, Melanocortin receptors, Sexual distress, Female sexual health. These areas describe investigation, not established personal benefit.
3 sources FDA statusIs PT-141 / Bremelanotide FDA approved?
Current U.S. status for PT-141 / Bremelanotide: Bremelanotide is FDA approved as Vyleesi only for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not indicated for men, postmenopausal women, or sexual performance enhancement.
3 sources Sport statusIs PT-141 / Bremelanotide prohibited in sport?
Current sport-status snapshot for PT-141 / Bremelanotide: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.
3 sources Evidence limitsWhat are the main evidence limits for PT-141 / Bremelanotide?
An approval for Vyleesi does not validate every product sold as PT-141 or use in populations outside the label.
3 sourcesPRIMARY AND OFFICIAL SOURCES